Colorectal liver metastasis: towards the integration of conventional and molecularly targeted therapeutic approaches

Mario, Lise
2005 Frontiers in Bioscience  
Adjuvant treatments Whether the use of adjuvant chemotherapy after resection of liver CRC metastases can decrease the rate of disease recurrence is still a matter of debate. Results from RCT are controversial. A first study failed to show any survival benefit following adjuvant 5-fluorouracil (5-FU)based HAI chemotherapy (22), which is supported by subsequent non-randomized studies (23). Another RCT comparing adjuvant HAI/systemic chemotherapy to systemic chemotherapy alone showed a trend
more » ... howed a trend towards improvement in 2-year progression-free survival (PFS) (57% vs 42%, P=0.07) and an improved OS rate in the combined chemotherapy arm (86% vs 72%, P=0.03) (24). When the same research group compared surgery plus systemic (5-FU) and HAI (fluorodeoxyuridine, FUDR) chemotherapy with surgery alone, the 4-year recurrencefree survival was better in the chemotherapy arm (67% vs 156. Lane CS, S Nisar, W Griffiths, B Fuller, B Davidson, J Hewes, K Welham, L Patterson: Identification of cytochrome P450 enzymes in human colorectal metastases and the surrounding liver: a proteomic approach. Eur J Cancer 40, 2127-2134 (2004).
doi:10.2741/1761 pmid:15970559 fatcat:rlkxunucfna33litvbaxyv6a4a